Radiation Oncology Journal

The Korean Society for Radiation Oncology (대한방사선종양학회)
권호 표지

Apoptosis and Proliferative Activity of Non-Hodgkin's Lymphoma : Correlation with Bcl-2 and P53 Protein Expression

비호지킨림프종에서 아포프토시스 및 세포증식 : Bcl-2, P53 단백발현과의 관계

  • Oh, Yoon-Kyeong (Department of Therapeutic Radiology, Chosun University Hospital) ;
  • Lee, Mi-Ja (Department of Pathology, Chosun University Hospital) ;
  • Jeon, Ho-Jong (Department of Pathology, Chosun University Hospital)
  • 오윤경 (조선대학교 의과대학 치료방사선과학교실) ;
  • 이미자 (조선대학교 의과대학 병리학교실) ;
  • 전호종 (조선대학교 의과대학 병리학교실)
  • Published : 2002.03.01
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose : Tumor growth in a given neoplasm is the net result of cell proliferation and cell loss, and apoptosis is the most significant component of continuous cell loss in most tumors. In this study, we examined non-Hodgkin's lymphoma (NHL, n=67) immunohistochemically for the presence of Bcl-2 oncoprotein and P53 protein and compared apoptotic indices (Als) and Ki-67 proliferative indices (percentages of Ki-67 positive cells). Materials and Methods : 67 patients with NHL were evaluated : 3 low-grade and 64 intermediate-grade. The phenotype was determined in 65 cases : 47 $(70\%)$ were B cell type and 18 $(27\%)$ were T ceil type. Als and Ki-67 proliferative indices were determined immunohistochemically and the overexpression of P53 and Bcl-2 protein were also evalutated. Results : The overexpressions of Bcl-2 protein and P53 protein were found in $40\%$ (26/65) and $31\%$ (20/65). The Al ranged from $0\%\;to\;15\%$ (mean 2.16, median 1.2). Cellular Bcl-2, which counteracts apoptosis, was significantly (p=0.005) associated with Als. Ki-67 proliferative indices ranged from $1\%\;to\;91\%$ (mean 55.4), and P53 was significantly (p=0.000) associated with Ki-67 proliferative indices. A positive correlation between Als and Ki-67 proliferative indices was revealed (p=0.012) in Bcl-2 positive patients. Conclusion : In NHL, we observed a correlation between Als and Bcl-2 expression, between Ki-67 proliferative indices and P53 expression, and between Als and Ki-67 proliferative indices in Bcl-2 positive patients. Our results suggest that cell apoptosis may be inseparable from cell proliferation during tumor growth.

목적 : 종양의 성장은 세포의 증식과 소실의 순수한 결과이며, 대부분의 종양들에서 아포프토시스는 계속되는 세포 소실의 가장 중요한 부분을 차지하고 있다. 본 연구에서는 비호지킨림프종 환자들을 REAL 분류에 따라 재분류한 다음 면역조직화학 염색을 이용하여 아포프토시스 지수, Ki-67 세포증식지수, Bcl-2 단백 발현, P53 단백 발현을 관찰하여 종양의 성장에 영향을 주는 여러 인자들의 관련 양상을 알아보고자 하였다. 대상 및 방법 : 비호지킨림프종 환자 67명을 대상으로 하였다. Working Formulation을 이용하여 분류하였을 때 저등급이 3명, 중등급이 64명이었다. 세포 표현형은 전체 67명의 환자 중 47명$(70\%)$이 B세포 표현형이었고, 18명$(27\%)$이 T세포 표현형이었으며, 2명에서는 분류할 수 없었다. 환자의 파라핀 포매 조직을 이용하여 면역조직화학 염색을 실시하여 아포프토시스 지수와 Ki-67 세포증식지수, Bcl-2 단백발현, P53 단백발현을 관찰하였다. 결과 : Bcl-2 단백의 발현은 $40\%$ (26/65)에서 양성 반응을 보였다. P53 단백의 발현은 $31\%$ (20/65)에서 보였다. 아포프토시스 지수는 $0\%$와 $15\%$사이의 범위에 있었으며 평균은 2.16이고 중앙값은 1.2이었다. 아포프토시스 지수는 세포 표현형이나 P53 단백발현 여부에 따라 의미 있는 차이를 보이지 않았으나, Bcl-2 단백발현 여부에 따라서는 통계학적으로 의미 있는 차이를 보였다(p=0.005). Bcl-2 단백발현이 양성이면 아포프토시스 지수가 낮았다. Ki-67 세포증식지수는 $1\%$와 $91\%$ 사이의 범위에 있었으며 평균은 $55.4\%$이었다. Ki-67 세포증식지수는 세포표현형이나 B치-2 단백발현 여부에 따라 의미 있는 차이를 보이지 않았으나, P53 단백발현 여부에 따라서는 통계학적으로 의미있는 차이를 보였다(p=0.000). 전체 환자군에서는 아포프토시스 지수와 Ki-67 세포증식지수 사이에 관련이 없었으나, Bcl-2 단백발현 양성인 환자에서는 아포프토시스 지수가 증가하면 Ki-67 세포증식지수가 증가하는 경향이 있었다(p=0.012). 결론 : Bcl-2 단백발현이 양성이면 아포프토시스 지수가 낮았고, P53 단백발현이 양성이면 Ki-67 세포증식지수는 높았다. 또한 Bcl-2 양성인 환자에서는 아포프토시스 지수와 Ki-67 세포증식지수사이의 양성 연관성을 보였는데 이는 아포프토시스가 종양의 성장에 있어서 세포의 증식과 별도로 분리하여 생각할 수 없는 것임을 시사해준다고 본다.

Keywords

References

  1. Grogan TM, Lippman SM, Spier CM, et al. Independent prognostic significance of a nuclear proliferation antigen in diffuse large cell lymphomas as determined by the monoclonalantibody Ki-67. Blood 1988;71:1157-1160
  2. Miller TP, Grogan TM, Dahlberg S, et al. Prognostic significance of the Ki-67- associated proliferative antigen in aggressive non-Hodgkin's lymphomas: a prospective southwest oncology group trial. Blood 1994:83:1460-1466
  3. Leoncini L, Vecchio MTD, Megha T, et al. Correlations between apcototc and proliferative indices in malignant nonHodgkin's lymphomas. Am J Pathol 1993:142:755-763
  4. Leoncini L, Vecchio MTD, Spina D, et al. Presence of the bcl-2 protein and apoptosis in non-Hodgkin lymphomas with diffuse growth pattern. Int J Cancer 1995:61:826-831
  5. Korkolopoulou P, Angelopoulou MK, Kontopidou F, et al. Prognostic relevance of apoptotic cell death in non-Hodgkin's lymphomas: a multivariate survival analysis including Ki-67 and p53 oncoprotein expression. Histopathology 1998:33:240-247
  6. Du M, Singh N, Husseuin A, Isaacson PG and Pan L. Positive correlation between apoptotic and proliferative indices in gastrointestinal lymphomas of mucosa-associated lymphoidtissue (MALT). J Pathol 1996;178:379-384 https://doi.org/10.1002/(SICI)1096-9896(199604)178:4<379::AID-PATH487>3.0.CO;2-J
  7. Gisbertz lAM, Schouten HC, Bot FJ, Arends JW. Cellturnover parameters in small and large cell varieties of primary intestinal non-Hodgkin's lymphoma. Cancer 1998;83:158-165 https://doi.org/10.1002/(SICI)1097-0142(19980701)83:1<158::AID-CNCR21>3.0.CO;2-V
  8. Takano Y, Saegusa M, Ikenaga M, and Okayasu I. Apoptosis and proliferative activity of non-Hodgkin's lymphomas : comparison with expression of bcl-2, p53 and c-mycproteins. Pathol International 1997:47:90-94
  9. Hall PA, Richards MA, Gregory WM, d'Ardenne AJ, Lister TA, and Stansfeld AG. The prognostic value of Ki67 immunostaining in non-Hodgkin's lymphoma. J Pathol 1998;154:223-235 https://doi.org/10.1002/path.1711540305
  10. Kalogeraki A, Tzardi M, Panagiotides I, et al. MIB1 (Ki67) expression in non-Hodgkin's lymphomas. Anticancer Res 1997;17:487-492 https://doi.org/10.1097/00001813-200606000-00001
  11. Park SS, Huh JR, Lee SS, Kang YK, Heo DS, and Kim CW. Correlation between clinical outcome and proliferationindex in diffuse large B-Cell lymphoma. Korean J Pathol 1999;33:475-482
  12. Han JH, Yang WI, Kim TS. Prognostic implications of Ki67 labelling index and p53, bcl-2 protein expression in the primary central nervous system lymphoma. Korean J Pathol 2000;34:456-464
  13. Czader M, Mazur J, Pettersson M, et al. Prognostic significance of proliferative and apoptotic fractions in low gradefollicle center cell-derived non-Hodgkin's lymphomas. Cancer 1996;77:1180-1188 https://doi.org/10.1002/(SICI)1097-0142(19960315)77:6<1180::AID-CNCR26>3.0.CO;2-X
  14. Slymen D, Miller TP, Lippman SM, et al. Immunobiologicfactors predictive of clinical outcome in diffuse large- cell lymphoma. J Clin Oncol 1990;8:986-993 https://doi.org/10.1200/JCO.1990.8.6.986
  15. Soini Y, Raunio H, Paakko P. High-grade malignant nonHodgkin's lymphomas differ from low-grade lymphomas in the extent of apoptosis and their expression of bcl-2, mcl-1, bax and p53. Tumor Biol 1998;19:176-185 https://doi.org/10.1159/000030005
  16. Cotter TG, Lennon SV, Glynn JG, Martin SJ . Cell deathvia apoptosis and its relationship to growth. Development and differentiation of both tumours and normal cells. Anticancer Res 1990;10:1153-1160
  17. Wyllie AH. Apoptosis Br J Cancer 1993;67:205-208
  18. Piris MA. Pezella F, Martinez-z Montero JC, Orradre JL, et al. P53- and bcl-2 expression in high-grade B-cell lymphomas : correlation with survival time. Br J Cancer 1994;69:337-341 https://doi.org/10.1038/bjc.1994.61
  19. Kramer MHH, Hermans J, Parker ADG, et al. Clinicalsignificance of bcl2 and p53 protein expression in diffuselarge B-cell lymphoma : a population-based study. J Clin Oncol 1996;14:2131-2138 https://doi.org/10.1200/JCO.1996.14.7.2131
  20. Koduru PRK, Raju K, Vadmal V, et al. Correlationbetween mutation in P53, p53 expression, cytogentics, histologic type, and survival in patients with B-cell non-Hodgkin's lymphoma. Blood 1997;90:4078-4091
  21. Reed JC. BcI-2 and the regulation of programmed cell death. J Cell Biol 1994;124:1-6 https://doi.org/10.1083/jcb.124.1.1
  22. Wheaton S, Netser J, Guinee D, Rahn M and Perkins S. BcI-2 and Bax protein expression in indolent versusaggressive B-cell non-Hodgkin's lymphomas. Human Pathol 1998;29:820-825 https://doi.org/10.1016/S0046-8177(98)90451-8
  23. Hill ME, MacLennan KA, Cunningham DC, et al. Prognostic significance of Bcl-2 expression and bcl-2 majorbreakpoint region rearrangement in diffuse large cell nonHodgkin's lymphoma: a British National Lymphoma Investigation Study. Blood 1996;88:1046-1051
  24. Hermine O, Haioun C, Lepage E, et al. Prognostic significance of bcl-2 protein expression in aggressive nonHodgkin's lymphoma. Blood 1996;87:265-272
  25. Logsdon MD, Meyn RE, Besa PC, et al. Apoptosis and the bcl-2 gene family - patterns of expression and prognostic value in stage I and II follicular center lymphoma. Int J Radiat Oncol Biol Phys 1999;44:19-29 https://doi.org/10.1016/S0360-3016(98)00455-6
  26. Offit K, Coco FL, Louie DC, et al. Rearrangement of the bcl-6 gene as a prognostic marker in diffuse large-cell lymphoma. N Engl J Med 1994;331:74-80 https://doi.org/10.1056/NEJM199407143310202
  27. Gascoyne RD, Adomat SA, Krajewski S, et al. Prognostic significance of BcI-2 protein expression and bcl-2 generearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood 1997;90:244-251
  28. Lee MJ, Jeon HJ, Chung CD, Park YH, Kim M. REAL classification and expression of Cyclin D1, BcI-2 , p53 and BcI- 6 protein in non-Hodgkin's lymphoma. Med J Chosun Univ 2001;26:32-39
  29. Ko YH, Kim CW, Park CS, et al. REAL classification of malignant lymphomas in the Republic of Korea. Cancer 1998;83:806-812 https://doi.org/10.1002/(SICI)1097-0142(19980815)83:4<806::AID-CNCR26>3.0.CO;2-V
  30. Komaki R, Fujii T, Perkins P, et al. Apoptosis and mitosis as prognostic factors in pathologically staged N1 nonsmall cell lung cancer. Int J Radiat Oncol Biol Phys 1996;36:601-605 https://doi.org/10.1016/S0360-3016(96)00351-3
  31. Wheeler JS, Stephens L, Eifel P, et al. Apoptosis as a predictor of tumor response to radiation in stage IB cervicaladenocarcinoma. Int J Radiat Oncol Biol Phys 1995;32:1487-1493 https://doi.org/10.1016/0360-3016(95)00156-S
  32. Levine EL, Davidson SE, Roberts SA, Chadwick CA, Potten CS, West CML. Apoptosis as predictor of response to radiotherapy in cervical carcinoma. Lancet 1994; 344:472
  33. Chung EJ, Seong J, Yang WI, et al. Spontaneous apoptosis as a predictor of radiotherapy in patients with stage llB squamous cell carcinoma of the uterine cervix. Acta Oncol 1999;38:449-454 https://doi.org/10.1080/028418699431979
  34. Lera J, Lara PC, Perez S, Cabrera JL, Santana C. Tumor proliferation, p53 expression, and apoptosis in laryngealcarcinoma: relation to the results of radiotherapy. Cancer 1998;83:2493-2501 https://doi.org/10.1002/(SICI)1097-0142(19981215)83:12<2493::AID-CNCR13>3.0.CO;2-C
  35. Aihara M, Scardino PT, Truong LD, et al. The frequencyelates with the prognosis of Gleason grade 3 adenocarcinoma of the prostate. Cancer 1995;75:522-529 https://doi.org/10.1002/1097-0142(19950115)75:2<522::AID-CNCR2820750215>3.0.CO;2-W